A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease.
Matthieu AllezBruce E SandsBrian G FeaganGeert D'HaensGert De HertoghCharles W RandallBin ZouJewel JohannsChristopher O'BrienMark CurranRory RebuckMei-Lun WangNina SabinsThomas BakerTaku KobayashiPublished in: Journal of Crohn's & colitis (2023)
Tesnatilimab was well tolerated. The efficacy of tesnatilimab in patients with CD was significant for the primary endpoint in Part 1; however, no dose-response signal was detected for the primary endpoint in Part 2. Based on these inconsistent findings, tesnatilimab was not considered an effective treatment for patients with CD and no further development is planned.